Get started
Humacyte, Inc.Humacyte, Inc.Humacyte, Inc.

Humacyte, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HUMA chart


Full chart

HUMA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪445.19 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.34 USD
Net income (FY)
‪−110.78 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪104.37 M‬
Beta (1Y)
0.49

Employees


Employees (FY)
183
Change (1Y)
+19 +11.59%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−605.33 K‬ USD

About Humacyte, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Laura E. Niklason
Website
humacyte.com
Headquarters
Durham
Founded
2004
FIGI
BBG00XPPT7S7
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HUMA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of HUMA is 4.64 USD — it has decreased by −2.26% in the past 24 hours. Watch Humacyte, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Humacyte, Inc. stocks are traded under the ticker HUMA.
HUMA stock has fallen by −20.64% compared to the previous week, the month change is a −21.72% fall, over the last year Humacyte, Inc. has showed a 63.96% increase.
We've gathered analysts' opinions on Humacyte, Inc. future price: according to them, HUMA price has a max estimate of 25.00 USD and a min estimate of 6.00 USD. Watch HUMA chart and read a more detailed Humacyte, Inc. stock forecast: see what analysts think of Humacyte, Inc. and suggest that you do with its stocks.
HUMA reached its all-time high on Sep 1, 2021 with the price of 17.45 USD, and its all-time low was 1.96 USD and was reached on Dec 30, 2022. View more price dynamics on HUMA chart.
See other stocks reaching their highest and lowest prices.
HUMA stock is 74.38% volatile and has beta coefficient of 0.49. Track Humacyte, Inc. stock price on the chart and check out the list of the most volatile stocks — is Humacyte, Inc. there?
Today Humacyte, Inc. has the market capitalization of ‪597.02 M‬, it has decreased by −11.12% over the last week.
Yes, you can track Humacyte, Inc. financials in yearly and quarterly reports right on TradingView.
Humacyte, Inc. is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
HUMA earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.25 USD resulting in a −32.45% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Humacyte, Inc. earnings.
Humacyte, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪214.29 K‬ USD.
HUMA net income for the last quarter is ‪−39.20 M‬ USD, while the quarter before that showed ‪−56.66 M‬ USD of net income which accounts for 30.82% change. Track more Humacyte, Inc. financial stats to get the full picture.
No, HUMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 183.00 employees. See our rating of the largest employees — is Humacyte, Inc. on this list?
Like other stocks, HUMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Humacyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Humacyte, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Humacyte, Inc. stock shows the sell signal. See more of Humacyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.